Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate the efficacy and safety of BG2109 administered
orally once daily at a dose of 100 mg alone or of 200 mg in combination with add-back hormone
replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus
placebo, while under randomized treatment, in the management of moderate to severe
endometriosis-associated pain (EAP) in chinese women with surgically confirmed endometriosis